c‐MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas

[1]  B. Furlow.  Tobacco control, lung cancer, and tuberculosis in Singapore. , 2018, The Lancet Respiratory Medicine.

[2]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[3]  A. Furlan,et al.  Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers , 2017, Journal of the National Cancer Institute.

[4]  N. Girard,et al.  MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung , 2017, Oncotarget.

[5]  K. O'Byrne,et al.  Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Yufeng Shen,et al.  Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Mok,et al.  MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis , 2016, Clinical Cancer Research.

[8]  Dong-Wan Kim,et al.  MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. , 2015, Lung cancer.

[9]  A. Warth,et al.  Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? , 2015, Diagnostic Pathology.

[10]  S. Serrano,et al.  MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC) , 2015, Oncotarget.

[11]  Mark Rosenzweig,et al.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. , 2015, Cancer discovery.

[12]  E. Brambilla,et al.  On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. , 2014, Lung cancer.

[13]  N. Girard,et al.  Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  K. Warner,et al.  The potential impact of smoking control policies on future global smoking trends , 2012, Tobacco Control.

[15]  E. Brambilla,et al.  Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  Jeffrey W. Clark,et al.  Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  A. Marchetti,et al.  Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.